Table 1.
Primary series absolute VE by Omicron subvariant from studies that include subvariant-specific estimates over time since final dose.
| Study (Country, Vaccine) | Outcome | Age group (years) | Time interval since last dose used for VE estimate | Median of time interval since last dose (days) |
2 dose VE (95 % CI) |
|||
|---|---|---|---|---|---|---|---|---|
| BA.1 | BA.2* |
BA.1/BA.2* |
BA.4/BA.5 | |||||
| Chemaitelly et al (Qatar, BNT162b2) [29] |
Symptomatic disease | All ages | 1–3 m | 46.6 (33.4, 57.2) | 51.7 (43.2, 58.9) | |||
| 4–6 m | 8.8 (-4.1, 20.1) | 12.4 (3.8, 20.3) | ||||||
| ≥7 m | −17.8 (-28.2, −8.2) | −12.1 (−19.1, −5.5) | ||||||
| Chemaitelly et al (Qatar, mRNA-1273) [29] |
1–3 m | 71.0 (24.0, 89.0) | 35.9 (-5.9, 61.2) | |||||
| 4–6 m | 31.3 (19.1, 41.7) | 9.9 (-0.3, 19.0) | ||||||
| ≥7 m | −10.2 (–23.1, 1.3) | −20.4 (-30.2, −11.2) | ||||||
| Collie et al (South, Africa, BNT162b2) [21] |
Hospitalization (excluding admissions unlikely related to COVID-19) | ≥18 | 14–27 d | 80.3 (62.8, 89.5) | ||||
| 1–2 m | 61.3 (54.7, 66.9) | |||||||
| 3–4 m | 56.3 (51.6, 60.5) | 47.4 (19.9, 65.5) | ||||||
| 5–6 m | 45.6 (39.3, 51.3) | 26.3 (7.1, 41.6) | ||||||
| 7–8 m | 38.4 (16.9, 54.4) | 23.6 (11.1, 34.3) | ||||||
| ≥9 m | 19.3 (6.3, 30.5) | |||||||
| Link-Gelles et al (USA, any mRNA) [25], [26] |
Emergency department or urgent care encounters for COVID-like illness | ≥18 | 14–149 d | 107 (BA.1), 104 (BA.2), 105 (BA.4/BA.5) |
47 (44, 50) | 51 (38, 60) | 47 (33, 58) | |
| ≥150 d | 267 (BA.1), 352 (BA.2), 424 (BA.4/BA.5) |
39 (37, 41) | 12 (7, 17) | 28 (24, 31) | ||||
| Hospitalization with COVID-like illness | 14–149 d | 105 (BA.1), 102 (BA.2) |
68 (63, 73) | 57 (19, 77) | ||||
| ≥150 d | 289 (BA.1), 371 (BA.2), 450 (BA.4/BA.5) |
61 (58, 63) | 24 (12, 35) | 25 (17, 32) | ||||
| Surie et al (USA, any mRNA) [30] |
Hospitalization with COVID-like illness | ≥18 | 14–150 d | 111 (BA.1/BA.2), 102 (BA.4/BA.5) | 63 (46, 75) | 83 (35, 96) | ||
| ≥150 d | 290 (BA.1/BA.2), 430 (BA.4/BA.5) | 34 (20, 46) | 37 (12, 55) | |||||
| Tartof et al (USA, BNT162b2) [31], [32] |
Emergency department admissions for acute respiratory infection | ≥18 | <6 m | 42 (31, 52) | 27 (-11, 52) | 30 (-86, 74) | ||
| ≥6 m | 19 (6, 31) | 12 (-10, 31) | 44 (20, 61) | |||||
| Hospitalization for acute respiratory infection | <6 m | 54 (38, 65) | 56 (-2, 81) | |||||
| ≥6 m | 32 (16, 45) | 56 (28, 73) | −4 (-118, 50) | |||||
| Grewal et al (Canada, any mRNA) [28] |
Hospitalization due to or partially due to COVID-19 | 50–59 | 240–299 d | 83 (76, 88) | 87 (43, 97) | |||
| ≥300 d | 83 (74, 89) | 56 (30, 72) | ||||||
| 60–69 | ≥300 d | 79 (71, 86) | 43 (16, 61) | |||||
| 70–79 | ≥300 d | 80 (72, 86) | 48 (25, 64) | |||||
| ≥ 80 | ≥300 d | 72 (62, 79) | 40 (18, 56) | |||||
Abbreviations: VE = vaccine effectiveness, CI = confidence interval, d = days, m = months. *BA.2.12.1 was not distinguished from BA.2 for all included studies.